ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020
Geneva, Switzerland and Boston, MA January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today announced that Company Management will be participating in the JP Morgan Healthcare Conference taking place January 13-16, 2020 in San Francisco.
Geneva, Switzerland and Boston, MA – January 7, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will be participating in the JP Morgan Healthcare Conference taking place January 13-16, 2020 in San Francisco. ObsEva will present on Wednesday, January 15, 2020 at 3:30 p.m. Pacific Time (PT).
The presentation webcast will be available in the “Investors” section of ObsEva’s website www.ObsEva.com.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
+1 857 972 9347 Office
+1 781 366 5726 Mobile
###
Attachment
